Home › Research › Treatments
Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular
Paulina Elizabeth Bombón-Albán. Acta neurológica colombiana, 2026-08-27
Topic: Brain proteins, microglia and lab models
Plain-language summary
La aprobación de lecanemab y donanemab para el tratamiento de la enfermedad de Alzheimer temprana plantea nuevos desafíos para la neurología vascular, principalmente por la aparición de anomalías en las imágenes relacionadas con el amiloide (ARIA). Estas pueden manifestarse como edema vasogénico o derrames sulcales (ARIA-E) y como microhemorragias, siderosis superficial o macrohemorragias (ARIA-H). Entre sus principales factores de riesgo se encuentran el genotipo APOE ε4 y la dosis del fármaco. Aunque suelen ser hallazgos radiológicos, pueden ocasionar déficits neurológicos focales, crisis epilépticas, cefalea o encefalopatía, síntomas que pueden confundirse con eventos cerebrovasculares agudos. La coexistencia de enfermedad de Alzheimer, angiopatía amiloide cerebral, ARIA y enfermedad cerebrovascular exige reconsiderar el uso de anticoagulantes y trombolíticos debido al riesgo de hemorragia intracerebral. Ante la sospecha de ictus en pacientes tratados con terapias anti-β-amiloide, se recomienda realizar una resonancia magnética urgente para descartar ARIA. En casos de oclusión de grandes vasos, la trombectomía mecánica podría ser una alternativa de reperfusión. Se requieren protocolos específicos y una mayor integración entre la neurología cognitiva y vascular para garantizar decisiones terapéuticas seguras.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bombón-Albán, P. E. (2026). Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular. Acta neurológica colombiana. https://doi.org/10.22379/anc.2188
Vancouver
Bombón-Albán PE. Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular. Acta neurológica colombiana. 2026. doi:10.22379/anc.2188.
BibTeX
@article{bombonalban2026-7db0e4e9,
author = {Bombón-Albán, Paulina Elizabeth},
title = {{Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular}},
journal = {Acta neurológica colombiana},
year = {2026},
doi = {10.22379/anc.2188},
url = {https://doi.org/10.22379/anc.2188}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Aunque suelen ser hallazgos radiológicos, pueden ocasionar déficits neurológicos focales, crisis epilépticas, cefalea o encefalopatía, síntomas que pueden confundirse con eventos cerebrovasculares agudos.
- La coexistencia de enfermedad de Alzheimer, angiopatía amiloide cerebral, ARIA y enfermedad cerebrovascular exige reconsiderar el uso de anticoagulantes y trombolíticos debido al riesgo de hemorragia intracerebral.
- Ante la sospecha de ictus en pacientes tratados con terapias anti-β-amiloide, se recomienda realizar una resonancia magnética urgente para descartar ARIA.
- En casos de oclusión de grandes vasos, la trombectomía mecánica podría ser una alternativa de reperfusión.
- Se requieren protocolos específicos y una mayor integración entre la neurología cognitiva y vascular para garantizar decisiones terapéuticas seguras.
Why it matters
The approval of lecanemab and donanemab for early Alzheimer's disease raises new challenges for vascular neurology, mainly because of ARIA, which can appear as brain edema or sulcal effusions (ARIA-E) and as microhemorrhages, superficial siderosis, or macrohemorrhages (ARIA-H). The authors note that APOE ε4 genotype and drug dose are main risk factors, that ARIA symptoms can be mistaken for acute cerebrovascular events, and that the coexistence of Alzheimer's disease, cerebral amyloid angiopathy, ARIA, and cerebrovascular disease requires reconsidering the use of anticoagulants and thrombolytics.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta neurológica colombiana) |
| Journal's citation record | 0 / 4 | Acta neurológica colombiana: journal h-index 11 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Paulina Elizabeth Bombón-Albán: h-index 3 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Pontificia Universidad Católica del Ecuador: institution h-index 151 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.